ClinicalTrials.gg
Not yet recruitingNCT07938476Bifido i18Updated Nov 16, 2026

Effects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early Life

An interventional study of Bifidobacterium longum subsp. infantis i18 and Placebo in Allergy, Gastrointestinal Symptoms and Gut -Microbiota, sponsored by DiproBio (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 0 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by DiproBio (Shanghai) Co., Ltd. · Not applicable, Interventional, and Prevention

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
0 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Hypersensitivity with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Hypersensitivity · China.

Planned enrollment
4th of 19
455 · median 188
Started
2026
with 4 others
No phase
10 of 34
3 open now
Registered
34th of 34
by date
Lead sponsor
1 of 34
DiproBio (Shanghai) Co., Ltd.

Among the 34 studies in Hypersensitivity with a site in China, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, and was the 34th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

9 of the 34 studies in Hypersensitivity with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 0 Months to 36 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Hypersensitivity with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.

03

Conditions studied

  • Allergy
  • Gastrointestinal Symptoms
  • Gut -Microbiota

Browse trials for

Keywords

  • INFANT
  • BIFIDO
  • HEALTHY
04

Who can participate

Ages eligible
0 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

For the Probiotic and Placebo Groups:

  1. Healthy infants and young children aged 0-36 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, receiving formula feeding and/or mixed feeding.
  2. Classified as being at high risk according to the study-defined assessment criteria.
  3. No clinically diagnosed allergic disease at enrollment.
  4. Written provided by the legal guardian.

For the Observational Reference Group:

  1. Healthy infants aged 0-6 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, exclusively breastfed.
  2. Classified as being at high risk according to the study-defined assessment criteria.
  3. No clinically diagnosed allergic disease at enrollment.
  4. Written informed consent provided by the legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Maternal history of metabolic or infectious diseases.
  2. High-risk pregnancy, or maternal history of alcohol, drug, or other substance abuse during pregnancy.
  3. Antibiotic use within 4 weeks before enrollment.
  4. Probiotic product use within 4 weeks before enrollment; for infants younger than 1 month, any use since birth.
  5. therapy before enrollment.
  6. Acute or chronic disease within 4 weeks before enrollment that may significantly affect growth and development.
  7. Congenital malformations or birth defects.
  8. Malnutrition requiring hospitalization.
  9. Known allergy to any component of the study probiotic product.
  10. Participation in another clinical trial or use of any drug within 3 months before screening; for infants younger than 3 months, any such participation or use since birth.
  11. Any other condition considered by the investigator to potentially affect participant safety or interpretation of study data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
455 participants (estimated)

Study arms

  • Experimental
    Probiotic Group

    Dietary Supplement: Bifidobacterium longum subsp. infantis i18

  • Placebo comparator
    Placebo Group

    Dietary Supplement: Placebo

  • No intervention
    Observational Reference Group

Interventions

  • Dietary supplementBifidobacterium longum subsp. infantis i18

    Bifidobacterium longum subsp. infantis i18 supplementation.

  • Dietary supplementPlacebo

    Matching placebo without the probiotic intervention

06

What researchers measure

Primary outcomes

  1. Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire

    Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.

Secondary outcomes

  1. Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire

    Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.

  2. Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire

    Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.

  3. Feeding pattern as assessed with the structured feeding questionnaire

    Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.

  4. Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards

    Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.

  5. Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.

    Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.

07

Study locations

1 site
  • First Hospital Hebei North University
    Zhangjiakou, Hebei, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 24 industry-sponsored interventional studies with no phase under Hypersensitivity, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 11. This study's planned 13 months is above that.

Counting every sponsor, half of 174 studies reached it within 20 months; a quarter within 5 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938476
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Jie Yuan
Contact
19821872781@163.com
+86 19821872781

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion